At a glance
- Source: Sugarcane (Saccharum officinarum) wax
- Standardization: 95% total policosanols; ≥65% octacosanol (1-octacosanol)
- Form: Powder
- Item Code: 8847
What PoliSure™ Is
Policosanol is a defined mixture of long-chain primary aliphatic alcohols (typically C24 through C34), of which 1-octacosanol (C28) is the predominant component. The mixture is extracted and purified from the outer wax of sugarcane stalks and refined to a high-purity powder. PoliSure™ delivers a tightly controlled policosanol profile suited for cardiovascular and lipid-support formulations.
Mechanism
Policosanol’s biological activity is attributed primarily to octacosanol and triacontanol. Proposed mechanisms include modulation of HMG-CoA reductase activity (distinct from the direct enzyme inhibition produced by statins), influence on cholesterol biosynthesis, and effects on platelet aggregation and HDL functionality. Independent research has produced mixed results across populations and source materials, and formulators should evaluate the published literature carefully when constructing label claims (see regulatory note below).
Why Formulators Choose PoliSure™
- High-purity 95% concentrate enables compact dose forms.
- Defined octacosanol content for consistent label claims.
- Sourced through GCI’s long-standing relationships with sugarcane-wax processors.
Where PoliSure™ Fits
Dosage formats: capsules, tablets, softgels.
Industries served: dietary supplements; functional food.
Technical Specifications
Request the current specification and lot-specific certificate of analysis for your selected grade.
| Detail | Information |
|---|---|
| Item Code | 8847 |
| Common Name | Policosanol |
| Source | Sugarcane (Saccharum officinarum) wax |
| Standardization | ≥95% total policosanols; ≥65% octacosanol |
| Solubility | Insoluble in water; soluble in lipid carriers |
For test method, appearance, particle size, loss on drying, heavy metals, microbiology, allergens, gmo status, origin, shelf life, request the current product documentation.
Ordering Information
| Detail | Information |
|---|---|
| Standard packaging | Confirm the available pack size with your quote |
| MOQ | Quoted for the selected ingredient and order quantity |
| Lead time | Request current availability and delivery timing |
| Sample availability | Yes |
Quality, Compliance & Certifications
Request current certificates and product statements for the selected grade; certification availability is subject to verification.
- Distributed under cGMP and the GCI Sure™ program.
- Request the current specification and lot-specific certificate of analysis.
Often Formulated With
- CoQ10, ubiquinol — cardiovascular and statin-adjacent formulations.
- Plant sterols, red yeast rice — cholesterol-support formulations.
- Hawthorn, garlic (GarliSure™) — broader cardiovascular stacks.
Resources
- PoliSure™ specification — request through the technical documents form
- Current COA — request via form
Bring PoliSure™ Into Your Next Formulation
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent disease. PoliSure™ is a trademark of GCI Nutrients, Inc.
Research & references
Historical references carried forward from the ingredient microsite. Research on another preparation or formulation does not establish the performance of this GCI ingredient.
- Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Alvarez E. Medical Surgical Research Center, National Center for Scientific Research, Havana City, Cuba. Int J Clin Pharmacol Res. 2001;21(1):43-57.
- Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Medical Surgical Research Center, National Center for Scientific Research, Havana City, Cuba. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M186-92.
- Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. Enrique Cabrera Hospital, Havana, Cuba. Int J Clin Pharmacol Res. 1999;19(4):117-27.
- A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Canetti M, Moreira M, Mas R, Illnait J, Fernandez L, Fernandez J, Diaz E, Castano G. “Salvador Allende” Hospital, Havana, Cuba. Int J Clin Pharmacol Res. 1995;15(4):159-65.
- Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Castano G, Mas R, Arruzazabala ML, Noa M, Illnait J, Fernandez JC, Molina V, Menendez A. Medical Surgical Research Center, Havana, Cuba. Int J Clin Pharmacol Res. 1999;19(4):105-16.
- Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia. [Article in Spanish] Prat H, Roman O, Pino E. Centro Cardiovascular Hospital Clinico Universidad de Chile. Rev Med Chil. 1999 Mar;127(3):286-94.